Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 10/20 | 0.60 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.60 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.60 |
| ▸ | F2 | P00734 | 9/20 | 0.51 |
| ▸ | F10 | P00742 | 5/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | C1S | P09871 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29182120 | 0.81 | AKR1C3 (0.58) | — | |
| SCHEMBL3769909 | 0.80 | PRSS1 (0.55) | PRSS1PRSS2PRSS3F2 | |
| SCHEMBL4144843 | 0.78 | PRSS1 (0.57) | PRSS1PRSS2PRSS3F2F10 | |
| SCHEMBL11409405 | 0.78 | PRSS1 (0.53) | PRSS1PRSS2PRSS3F2 | |
| SCHEMBL3316767 | 0.76 | PRSS1 (0.54) | PRSS1PRSS2PRSS3F2F10 | |
| SCHEMBL428920 | 0.75 | PRSS1 (1.00) | PRSS1PRSS2PRSS3F2F10 | |
| Hydrochloric Acid SCHEMBL23541004 | 0.74 | PRSS1 (0.96) | PRSS1PRSS2PRSS3F2F10 | |
| SCHEMBL11556061 | 0.74 | LMNA (0.72) | — | |
| SCHEMBL4928156 | 0.74 | CYP3A4 (0.72) | — | |
| SCHEMBL4453562 | 0.74 | CES2 (0.53) | PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220054479-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885PRSS2 665/4885PRSS3 646/4885 |
| US-20220054479-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885PRSS2 665/4885PRSS3 646/4885 |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885PRSS2 665/4885PRSS3 646/4885 |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885PRSS2 665/4885PRSS3 646/4885 |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885PRSS2 665/4885PRSS3 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.